Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Assets (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Assets for 5 consecutive years, with $76.6 million as the latest value for Q4 2025.

  • Quarterly Assets fell 47.02% to $76.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.6 million through Dec 2025, down 47.02% year-over-year, with the annual reading at $76.6 million for FY2025, 47.02% down from the prior year.
  • Assets hit $76.6 million in Q4 2025 for Kezar Life Sciences, down from $97.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $317.5 million in Q2 2022 to a low of $76.6 million in Q4 2025.
  • Historically, Assets has averaged $196.5 million across 5 years, with a median of $189.5 million in 2024.
  • Biggest five-year swings in Assets: soared 132.85% in 2022 and later plummeted 47.02% in 2025.
  • Year by year, Assets stood at $217.9 million in 2021, then soared by 37.46% to $299.6 million in 2022, then dropped by 26.15% to $221.2 million in 2023, then plummeted by 34.6% to $144.7 million in 2024, then tumbled by 47.02% to $76.6 million in 2025.
  • Business Quant data shows Assets for KZR at $76.6 million in Q4 2025, $97.7 million in Q3 2025, and $109.1 million in Q2 2025.